#China #Shanghai #Henlius #Hanquyou #Serplulimab

Henlius Reports Strong Growth in 2025

Henlius, a notable player in the biopharmaceutical sector, recently announced its financial results for the year 2025, highlighting robust growth and a strong trajectory in innovation and global expansion. This marks the third consecutive year of profitability since the company recorded its first positive result in 2023, establishing its position as a sustainable entity in its field.

The company's revenue soared to 6.67 billion RMB in 2025, representing a 16.5% increase from the previous year. This growth is underpinned by a net profit of 0.83 billion RMB during the same period, reflecting the efficacy of Henlius’s strategic investments and operational enhancements. The organization's commitment to research and development also showed promising results, with R&D spending reaching 2.49 billion RMB, a significant 35.4% increase compared to last year. Consequently, the profit before R&D costs climbed to 2.34 billion RMB, marking a 26.2% rise, further demonstrating the company’s consistent and qualitative growth.

As the global market for biopharmaceuticals continues to evolve, Henlius has successfully expanded its operations, achieving total revenues of 5.77 billion RMB from international sales alone. This impressive performance was largely driven by increased revenue from core products, particularly Serplulimab (marketed as Hetronifly® in Europe) and HANQUYOU (Trastuzumab, known as HERCESSI™ in the USA and Zercepac® in Europe). In addition, strategic partnerships have also facilitated extra milestone payments, helping the company deepen its market presence beyond China. Specifically, the product revenue outside of China surpassed 200 million RMB, effectively doubling from the previous year, which is a remarkable achievement that underscores Henlius's expanding footprint.

Henlius's flagship product, Serplulimab, continues to gain traction in the international market, yielding a global revenue of 1.49 billion RMB, indicating a 13.7% year-over-year growth. Furthermore, revenue generated from its oncology products, specifically those used for breast cancer, reached 3.27 billion RMB during the reporting period. Beyond just selling new products, existing mature offerings are also contributing to a steady cash flow for the company.

The two dosage forms of HLX14 (Denosumab) were successfully launched in key markets including the United States, Germany, Spain, and the UK, generating a sales figure of 9.8 million RMB. Looking ahead, Henlius is well-positioned to advance its innovation pipeline, with pivotal compounds such as Dulpatatug (HLX22, an innovative anti-HER2 monoclonal antibody) and HLX43 (PD-L1-ADC) entering crucial phases of clinical trials.

Leveraging its integrated capabilities across research and development, clinical trials, regulatory affairs, production, and marketing, Henlius is accelerating its transformation into a global biopharma model deeply rooted in China. The company remains committed to providing high-quality biologics to patients worldwide, aiming to bring innovative and effective treatments to the global stage.

As Henlius continues to evolve and adapt to changing market dynamics, its focus on quality growth and sustainable profitability is expected to reinforce its position as a leader in the biopharmaceutical sector for years to come.